{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:16:47Z","timestamp":1782901007539,"version":"3.54.5"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["957121"],"award-info":[{"award-number":["957121"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.brainres.2025.149783","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:57:51Z","timestamp":1749898671000},"page":"149783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Unraveling the complexity of glioblastoma microenvironment: A comparative study of 3D and 2D cultures in response to combination drug therapy"],"prefix":"10.1016","volume":"1864","author":[{"given":"Rasoul","family":"Rashidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoudreza","family":"Hadjighassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Negahdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.brainres.2025.149783_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062852","article-title":"Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma","volume":"8","author":"Agarwal","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.brainres.2025.149783_b0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.pharep.2017.03.014","article-title":"Application of standard cell cultures and 3D in vitro tissue models as an effective tool in drug design and development","volume":"69","author":"Amelian","year":"2017","journal-title":"Pharmacol. Rep."},{"issue":"12","key":"10.1016\/j.brainres.2025.149783_b0015","doi-asserted-by":"crossref","DOI":"10.31557\/APJCP.2021.22.12.3993","article-title":"Combination therapy with PIK3R3-siRNA and EGFR-TKI erlotinib synergistically suppresses glioblastoma cell growth in vitro","volume":"22","author":"Amini","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3","key":"10.1016\/j.brainres.2025.149783_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173331","article-title":"Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer","volume":"12","author":"Azad","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2025.149783_b0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijbiomac.2021.06.083","article-title":"Preparation and characterization of 3D human glioblastoma spheroids using an N-octanoyl glycol chitosan hydrogel","volume":"185","author":"Bae","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/pharmaceutics15010059","article-title":"Tyrosine kinase inhibitors for glioblastoma multiforme: challenges and opportunities for drug delivery","volume":"15","author":"Brar","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0035","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.brainres.2025.149783_b0040","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.molpharmaceut.0c00968","article-title":"Development of a prodrug of camptothecin for enhanced treatment of glioblastoma multiforme","volume":"18","author":"Checa-Chavarria","year":"2021","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.brainres.2025.149783_b0045","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J. Oncol. Pract."},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0050","article-title":"Phase I\/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","volume":"2","author":"Chen","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"issue":"3","key":"10.1016\/j.brainres.2025.149783_b0055","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.brainres.2025.149783_b0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"issue":"13","key":"10.1016\/j.brainres.2025.149783_b0065","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1158\/1078-0432.CCR-16-0069","article-title":"Improving the predictive value of preclinical studies in support of radiotherapy clinical trials","volume":"22","author":"Coleman","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.brainres.2025.149783_b0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/2472555217689884","article-title":"A novel multiparametric drug-scoring method for high-throughput screening of 3D multicellular tumor spheroids using the celigo image cytometer","volume":"22","author":"Cribbes","year":"2017","journal-title":"SLAS Discov.: Adv. Life Sci. R&D"},{"issue":"5","key":"10.1016\/j.brainres.2025.149783_b0075","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.soncn.2018.10.001","article-title":"Epidemiology and overview of gliomas","volume":"34","author":"Davis","year":"2018","journal-title":"Seminars Oncol. Nurs. (WB Saunders)"},{"issue":"14","key":"10.1016\/j.brainres.2025.149783_b0080","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/sj.onc.1210850","article-title":"The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids","volume":"27","author":"De Witt Hamer","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0085","first-page":"555","article-title":"Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells","volume":"38","author":"Dong","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.brainres.2025.149783_b0090","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/brainsci11081025","article-title":"development and validation of a long-term 3D glioblastoma cell culture in alginate microfibers as a novel bio-mimicking model system for preclinical drug testing","volume":"11","author":"Dragoj","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.brainres.2025.149783_b0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4939-7021-6_12","article-title":"3D hanging drop culture to establish prostate cancer organoids","author":"Eder","year":"2017","journal-title":"3D Cell Culture: Methods Protocols"},{"issue":"4","key":"10.1016\/j.brainres.2025.149783_b0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/adt.2014.573","article-title":"Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors","volume":"12","author":"Edmondson","year":"2014","journal-title":"Assay Drug Dev. Technol."},{"issue":"12","key":"10.1016\/j.brainres.2025.149783_b0105","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4161\/cbt.11.12.15693","article-title":"Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death","volume":"11","author":"Eimer","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-11-18","article-title":"Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine","volume":"11","author":"Erguven","year":"2011","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibtech.2012.12.003","article-title":"Spheroid culture as a tool for creating 3D complex tissues","volume":"31","author":"Fennema","year":"2013","journal-title":"Trends Biotechnol."},{"issue":"6","key":"10.1016\/j.brainres.2025.149783_b0120","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/1535-7163.MCT-13-0854","article-title":"Culture dimensionality influences the resistance of glioblastoma stem-like cells to multikinase inhibitors","volume":"13","author":"Fernandez-Fuente","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.brainres.2025.149783_b0125","unstructured":"Flynn JP, Gerriets V. Imatinib. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551676\/. Updated 2 July 2022."},{"key":"10.1016\/j.brainres.2025.149783_b0130","article-title":"A simple hanging drop cell culture protocol for generation of 3D spheroids","volume":"51","author":"Foty","year":"2011","journal-title":"JoVE (J. Visualized Experiment.)"},{"issue":"11\u201312","key":"10.1016\/j.brainres.2025.149783_b0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/09553000701727531","article-title":"Experimental anti-tumor therapy in 3-D: spheroids\u2013old hat or new challenge?","volume":"83","author":"Friedrich","year":"2007","journal-title":"Int. J. Radiat Biol."},{"issue":"3","key":"10.1016\/j.brainres.2025.149783_b0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: considerations and practical approach","volume":"4","author":"Friedrich","year":"2009","journal-title":"Nat. Protoc."},{"issue":"21","key":"10.1016\/j.brainres.2025.149783_b0145","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.brainres.2025.149783_b0150","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jocn.2008.12.005","article-title":"The EGFRvIII variant in glioblastoma multiforme","volume":"16","author":"Gan","year":"2009","journal-title":"J. Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.brainres.2025.149783_b0155","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3390\/molecules22122209","article-title":"Developing an agent-based drug model to investigate the synergistic effects of drug combinations","volume":"22","author":"Gao","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.brainres.2025.149783_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189281","article-title":"The tumor microenvironment and dendritic cells: developers of pioneering strategies in colorectal cancer immunotherapy?","author":"Ghorbaninezhad","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA)-reviews on Cancer"},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-018-0211-8","article-title":"Combination therapy to checkmate glioblastoma: clinical challenges and advances","volume":"7","author":"Ghosh","year":"2018","journal-title":"Clin. Transl. Med."},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jcp.20320","article-title":"Three\u2010dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study","volume":"204","author":"Ghosh","year":"2005","journal-title":"J. Cell. Physiol."},{"issue":"8","key":"10.1016\/j.brainres.2025.149783_b0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.brainres.2025.149783_b0180","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jnci\/dji161","article-title":"Epidermal growth factor receptor, protein kinase B\/Akt, and glioma response to erlotinib","volume":"97","author":"Haas-Kogan","year":"2005","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.brainres.2025.149783_b0185","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s10495-015-1126-0","article-title":"Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2","volume":"20","author":"Haque","year":"2015","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.brainres.2025.149783_b0190","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin \u03b21\/FAK signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","article-title":"Multicellular tumor spheroids: an underestimated tool is catching up again","volume":"148","author":"Hirschhaeuser","year":"2010","journal-title":"J. Biotechnol."},{"issue":"10","key":"10.1016\/j.brainres.2025.149783_b0200","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oraloncology.2013.10.003","article-title":"Combination antiangiogenic therapy and radiation in head and neck cancers","volume":"50","author":"Hsu","year":"2014","journal-title":"Oral Oncol."},{"issue":"4","key":"10.1016\/j.brainres.2025.149783_b0210","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3892\/or.2015.3767","article-title":"Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer","volume":"33","author":"Imamura","year":"2015","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.brainres.2025.149783_b0215","first-page":"44","article-title":"siRNA-mediated inhibition of survivin gene enhances the anti-cancer effect of etoposide in U-937 acute myeloid leukemia cells","volume":"62","author":"Jafarlou","year":"2016","journal-title":"Cell. Mol. Biol."},{"issue":"8","key":"10.1016\/j.brainres.2025.149783_b0220","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/21691401.2017.1392969","article-title":"Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and survivin genes using small interfering RNA in human myelomonocytic leukaemia","volume":"46","author":"Jafarlou","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.brainres.2025.149783_b0225","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2007.04.019","article-title":"Hypoxia-inducible factors, stem cells, and cancer","volume":"129","author":"Keith","year":"2007","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0230","article-title":"Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells","volume":"429","author":"Khiabani","year":"2023","journal-title":"Experimental Cell Res."},{"key":"10.1016\/j.brainres.2025.149783_b0235","unstructured":"Kim TE, Murren JR. Erlotinib OSI\/Roche\/Genentech. Current opinion in investigational drugs (London, England: 2000). 2002;3(9):1385-95."},{"issue":"7","key":"10.1016\/j.brainres.2025.149783_b0240","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.21873\/anticanres.13527","article-title":"Tyrosine kinase inhibitors imatinib and erlotinib increase apoptosis of antimitotic drug-resistant KBV20C cells without inhibiting P-gp","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.brainres.2025.149783_b0245","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.yexcr.2012.01.014","article-title":"Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib","volume":"318","author":"Kinsella","year":"2012","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.brainres.2025.149783_b0250","doi-asserted-by":"crossref","unstructured":"Koledova Z. 3D coculture of mammary organoids with fibrospheres: a model for studying epithelial\u2013stromal interactions during mammary branching morphogenesis. 3D cell culture: methods and protocols. 2017:107-24. https:\/\/doi.org\/10.1007\/978-1-4939-7021-6_8.","DOI":"10.1007\/978-1-4939-7021-6_8"},{"issue":"3","key":"10.1016\/j.brainres.2025.149783_b0255","doi-asserted-by":"crossref","first-page":"F217","DOI":"10.1016\/S0304-419X(97)00022-X","article-title":"Protein tyrosine kinases and cancer","volume":"1333","author":"Kolibaba","year":"1997","journal-title":"Biochimica et Biophysica Acta (BBA)-reviews on Cancer"},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0260","first-page":"189","article-title":"Drug-drug interactions, safety, and pharmacokinetics of EGFR tyrosine kinase inhibitors for the treatment of non\u2013small cell lung cancer","volume":"9","author":"Kucharczuk","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"issue":"4","key":"10.1016\/j.brainres.2025.149783_b0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1087057104265040","article-title":"The use of 3-D cultures for high-throughput screening: the multicellular spheroid model","volume":"9","author":"Kunz-Schughart","year":"2004","journal-title":"J. Biomol. Screen."},{"issue":"7\u20138","key":"10.1016\/j.brainres.2025.149783_b0270","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.drudis.2011.01.009","article-title":"Biomarkers for simplifying HTS 3D cell culture platforms for drug discovery: the case for cytokines","volume":"16","author":"Lai","year":"2011","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","article-title":"In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor","volume":"91","author":"Le Coutre","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.brainres.2025.149783_b0280","first-page":"1494","article-title":"Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer","volume":"6","author":"Li","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.brainres.2025.149783_b0285","first-page":"3","article-title":"Glioblastoma genomics: a very complicated story","author":"Lombardi","year":"2017","journal-title":"Exon Publications"},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0290","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/biology3020345","article-title":"Advanced cell culture techniques for cancer drug discovery","volume":"3","author":"Lovitt","year":"2014","journal-title":"Biology"},{"issue":"8","key":"10.1016\/j.brainres.2025.149783_b0295","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-07-2250","article-title":"Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1\u2212\/\u2212\/Mdr1a\/1b\u2212\/\u2212(triple-knockout) and wild-type mice","volume":"7","author":"Marchetti","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"23","key":"10.1016\/j.brainres.2025.149783_b0300","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.brainres.2025.149783_b0305","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.canlet.2019.10.034","article-title":"Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways","volume":"469","author":"Nan","year":"2020","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.brainres.2025.149783_b0310","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.3390\/ijms241411696","article-title":"Involvement of both extrinsic and intrinsic apoptotic pathways in tridecylpyrrolidine-diol derivative-induced apoptosis in vitro","volume":"24","author":"Nosalova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbrc.2009.02.012","article-title":"bFGF rescues imatinib\/STI571-induced apoptosis of sis-NIH3T3 fibroblasts","volume":"381","author":"Ohshima","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ijms22010351","article-title":"Molecular mechanisms of treatment resistance in glioblastoma","volume":"22","author":"Ou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149783_b0325","first-page":"367","article-title":"3D cell cultures: mimicking in vivo tissues for improved predictability in drug discovery","volume":"47","author":"Padmalayam","year":"2012","journal-title":"Annu. Rep. Med. Chem."},{"issue":"10","key":"10.1016\/j.brainres.2025.149783_b0330","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nrm2236","article-title":"The third dimension bridges the gap between cell culture and live tissue","volume":"8","author":"Pampaloni","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.brainres.2025.149783_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119371","article-title":"Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens","volume":"219","author":"Pedron","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21873\/anticanres.11285","article-title":"Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme","volume":"37","author":"Polivka","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.brainres.2025.149783_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.952169","article-title":"Luteolin enhances erlotinib\u2019s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines","volume":"13","author":"Powe","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2025.149783_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113532","article-title":"Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia","volume":"221","author":"Puxeddu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.brainres.2025.149783_b0355","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1021\/acsmedchemlett.5b00128","article-title":"High-throughput screening of patient-derived cultures reveals potential for precision medicine in glioblastoma","volume":"6","author":"Quartararo","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.brainres.2025.149783_b0360","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2007.11.0304","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute organ dysfunction working group","volume":"26","author":"Ramanathan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.brainres.2025.149783_b0365","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s13402-019-00443-1","article-title":"The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells","volume":"42","author":"Ramis","year":"2019","journal-title":"Cell. Oncol."},{"issue":"3","key":"10.1016\/j.brainres.2025.149783_b0370","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1215\/15228517-2008-003","article-title":"Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma","volume":"10","author":"Reardon","year":"2008","journal-title":"Neuro Oncol."},{"issue":"suppl_7","key":"10.1016\/j.brainres.2025.149783_b0375","doi-asserted-by":"crossref","first-page":"vii32","DOI":"10.1093\/neuonc\/nov178","article-title":"Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy","volume":"17","author":"Reardon","year":"2015","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.brainres.2025.149783_b0380","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41420-021-00423-1","article-title":"Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models","volume":"7","author":"Riess","year":"2021","journal-title":"Cell Death Discov."},{"issue":"8","key":"10.1016\/j.brainres.2025.149783_b0385","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ctrv.2013.05.001","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients","volume":"39","author":"Roengvoraphoj","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.brainres.2025.149783_b0390","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.brainres.2025.149783_b0395","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/0955-0674(90)90085-S","article-title":"Designer microenvironments for the analysis of cell and tissue function","volume":"2","author":"Stoker","year":"1990","journal-title":"Curr. Opin. Cell Biol."},{"issue":"12","key":"10.1016\/j.brainres.2025.149783_b0400","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.brainres.2025.149783_b0405","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-03-3681","article-title":"AEE788: a dual family epidermal growth factor receptor\/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity","volume":"64","author":"Traxler","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.brainres.2025.149783_b0410","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.brainres.2025.149783_b0415","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1699-0463.1973.tb03573.x","article-title":"Determinants for the establishment of permanent tissue culture lines from human gliomas","volume":"81","author":"Westermark","year":"1973","journal-title":"Acta Pathologica Microbiologica Scandinavica Section A Pathology."},{"issue":"7","key":"10.1016\/j.brainres.2025.149783_b0420","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.brainres.2025.149783_b0425","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/bjc.2015.420","article-title":"Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant","volume":"114","author":"Zakaria","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"23","key":"10.1016\/j.brainres.2025.149783_b0430","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","article-title":"Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses","volume":"10","author":"Zhao","year":"2004","journal-title":"Clin. Cancer Res."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325003440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325003440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:23:03Z","timestamp":1777105383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899325003440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":86,"alternative-id":["S0006899325003440"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149783","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the complexity of glioblastoma microenvironment: A comparative study of 3D and 2D cultures in response to combination drug therapy","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149783"}}